Erythropoietin & Pediatric Cardiac Surgery

Status Terminated

Clinical Trial Summary

Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can cause damage to those organs. We hypothesize that a single dose of erythropoietin prior to the heart bypass portion of surgery may protect the infant human heart and brain from injury.

This randomized clinical trial will involve 120 children, age 6 weeks to 18 years, requiring heart bypass surgery for congenital heart defects.

Clinical Trial Description

Lack of bloodflow to the heart and brain when the heart is stopped during heart surgery can cause damage to those organs. A medicine already used in humans, erythropoietin, may protect the heart and brain of children born with heart defects during their surgical repair. In a rabbit model, erythropoietin did protect the hearts. We hypothesize that a single dose of erythropoietin prior to the heart bypass portion of surgery may protect the infant human heart and brain from injury.

For this randomized control trial, 120 children, age 6 weeks to 18 years, requiring heart bypass surgery for congenital heart defects, will be divided into four groups. Two groups will be children whose usual blood oxygen level is low because of their heart defect; the other two will be children with normal blood oxygen levels. Each child will be randomized to receive either erythropoietin or placebo 15 minutes prior to stopping the heart during their surgery.

Erythropoietin's protective function will be measured after surgery by: (1) amount of medication required to support heart function, (2) how well the heart pumps blood as seen by echocardiogram, (3) levels of chemicals produced by the body when heart or brain tissue injury occurs, (4) urine output and oxygen levels (5) time on ventilator support (6) ICU stay and (7) hospital stay. Heart tissue will be collected during surgery to determine how erythropoietin protects heart cells.

Statistical tests including ANOVA will test for similarities and differences among the groups on the measures of protection from injury.

Note - the study design was edited after the FDA released a warning about the use of erythropoietin. Only acyanotic patients were recruited therefore only 2 study groups are included. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00451698
Study type	Interventional
Source	Medical College of Wisconsin
Contact
Status	Terminated
Phase	N/A
Start date	October 2007
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04136379` - Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
Recruiting	`NCT02258724` - Swiss National Registry of Grown up Congenital Heart Disease Patients
Completed	`NCT01212289` - Use of ROTEM® in Pediatric Cardiac Surgical Patients	N/A
Recruiting	`NCT04090827` - The Transitioning Rural Adolescents to Adult Care Study	N/A
Completed	`NCT03311438` - Oral Health Intervention Program for Children With Congenital Heart Defects	N/A
Active, not recruiting	`NCT04271358` - Peer Coaching Intervention in Young Adults With Congenital Heart Disease	N/A
Recruiting	`NCT04106479` - NIRS in Congenital Heart Defects - Correlation With Echocardiography
Recruiting	`NCT04437069` - Improving Patient and Family Health Using Family-Centered Outcomes and Shared Decision-Making	N/A
Completed	`NCT04106154` - Impacting Children's Physical and Mental Health Through Kinesiology Support in Clinical Care	N/A
Recruiting	`NCT03297658` - Electro-acupuncture (EA) in Children Undergoing Procedures for Congenital Heart Defects.	N/A
Recruiting	`NCT04619745` - A Feasibility Study of Physical Activity After Surgical or Catheterization Intervention	N/A
Recruiting	`NCT03512613` - A Pilot Study- Monitoring Cerebral Blood Flow in Neonates With Congenital Heart Defects
Recruiting	`NCT05698277` - Automated Fetal Cardiac Function in Babies Affected by Heart Diseases
Completed	`NCT04056416` - Physical Activity Promotion in Children and Adolescents With Single Ventricle Physiology (MedBike)	N/A
Active, not recruiting	`NCT03110861` - Pulsta® Transcatheter Pulmonary Valve Korean Multicenter Study	N/A
Completed	`NCT02387944` - Bedside Evaluation of Coagulation in Children With Congenital Heart Disease	N/A
Completed	`NCT03348397` - Contegra Versus Pulmonary Homograft for Right Ventricular Outflow Tract Reconstruction in Newborns	N/A
Completed	`NCT02968264` - Tetralogy of Fallot for Life
Completed	`NCT03611374` - Regional Anesthesia for Cardiothoracic Enhanced Recovery (RACER) Study	N/A
Completed	`NCT03143348` - Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Erythropoietin and Pediatric Cardiac Surgery — EPO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms